OncoMatch/Clinical Trials/NCT05192122
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Is NCT05192122 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for multiple myeloma.
A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Disease stage
Required: Stage R-ISS I, R-ISS II, R-ISS III (Revised International Staging System (R-ISS))
Revised International Staging System (R-ISS) I,2 or 3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: maintenance therapy after ASCT — post-ASCT
Received at least 2 years of post ASCT maintenance (patients may have received any number of prior lines of therapy).
Cannot have received: allogeneic hematopoietic cell transplant
Prior allogeneic hematopoietic cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify